Patients who have undergone lung transplant frequently seek medical attention at community hospitals for familiar complaints such as cough, dyspnea, fever, diarrhea, or declining exercise tolerance. While these symptoms may appear routine, clinicians must approach them differently in this patient population because infection, rejection, airway complications, medication toxicity, and graft dysfunction can produce overlapping symptoms.

“The goal isn’t to turn the community hospital into a transplant center. It’s to make the initial care safer,” said Ashwini Ronghe, MBBS, during the CHEST 2026 session Lung Transplant Patients in the Community: Early Recognition, Initial Management, and Timely Referral on Tuesday, October 20, in Phoenix.
Dr. Ronghe, a pulmonary and critical care fellow at the University of Arizona, encouraged clinicians to begin with a simple question: What has changed from the patient’s baseline? Oxygen requirements, spirometry trends, prior imaging, microbiology results, and immunosuppression regimens often provide more useful information than symptoms alone.
“The baseline matters,” she noted, particularly when evaluating new hypoxemia or declining lung function.
Dr. Ronghe cautioned against anchoring on common diagnoses. A presumed pneumonia may represent rejection, while a positive viral test does not exclude bacterial infection or evolving graft dysfunction. Likewise, recurrent wheezing or cough may reflect airway complications rather than asthma or bronchitis. Her message was to broaden the differential diagnosis and consider infection and allograft dysfunction simultaneously.
Communication with the transplant center emerged as another recurring theme. “The communication is an intervention itself,” Dr. Ronghe said, noting that transplant teams have access to prior cultures, rejection history, donor-recipient risk factors, and center-specific management plans. “That phone call should happen early and not after everything else has failed.”
She concluded with a framework for frontline clinicians: Know the patient’s baseline, evaluate infection and graft dysfunction together, remain vigilant about immunosuppressive medications and drug interactions, and coordinate early with the transplant center.
“We do need to recognize when the presentation is different, initiate safe care, and know when to escalate,” she said.
Drug interactions
Clinicians at community hospitals may be less familiar with transplant pharmacology, increasing the risk of drug-drug interactions and unsafe medication practices when patients who have undergone lung transplant are seen in those settings.

Session Chair Ramsey Hachem, MD, Chief of the Division of Respiratory, Critical Care, and Occupational Pulmonary Medicine at the University of Utah Spencer Fox Eccles School of Medicine, explained that maintenance immunosuppression requires precise management because many transplant medications operate within a narrow therapeutic window. Calcineurin inhibitors and mTOR inhibitors are particularly vulnerable to interactions through CYP3A4 and P-glycoprotein pathways, meaning even routine prescriptions can lead to toxicity or inadequate immunosuppression.
“When adding a new medication, always consider the possibility of drug-drug interactions,” Dr. Hachem said.
Using case examples, Dr. Hachem reviewed interactions involving azole antifungals, warfarin, amiodarone, direct-acting antivirals, and Paxlovid, highlighting situations in which tacrolimus levels rose to dangerous concentrations, resulting in renal injury and neurologic toxicity. In one example, a patient treated with Paxlovid developed a tacrolimus concentration nearly four times higher than the typical target range.
“Consult with the transplant center and your local friendly pharmacist often,” he advised. “Drug-drug interactions are common and can result in serious toxicity and morbidity.”
Image interpretation

Brett M. Elicker, MD, Professor of Clinical Radiology and Chief of the Cardiac and Pulmonary Imaging Section at the University of California, San Francisco, provided a practical, image-based framework for evaluating complications in patients who have undergone lung transplant. He organized complications according to timing, from immediate postoperative issues to complications occurring within the first year and years later.
Dr. Elicker noted that chest radiography remains useful for detecting pleural and extrapulmonary complications but has limited sensitivity and specificity for parenchymal disease.
“If you’re dealing with something in the lungs, it’s always good to have a very low threshold for getting a CT scan,” he said.
He also addressed one of the central diagnostic challenges in transplant medicine. “It is virtually impossible to distinguish infection from acute rejection,” Dr. Elicker said, noting that the two processes frequently coexist and often share imaging findings.
He discussed chronic lung allograft dysfunction, reviewing hallmarks of bronchiolitis obliterans syndrome, restrictive allograft syndrome, and acute fibrinous organizing pneumonia. He concluded by covering airway strictures, posttransplant lymphoproliferative disorder, and recurrence of native lung disease, and he reinforced the importance of interpreting imaging findings within their clinical and temporal context. The image is worth a thousand words, he said, but only when integrated with the patient’s broader transplant journey.
Whether evaluating new symptoms, prescribing medications, or interpreting imaging findings, panelists urged community hospital clinicians to look beyond routine explanations when caring for patients who have undergone lung transplant. Early recognition, careful coordination, and timely communication with transplant programs remain essential to safe, effective care.

Call for Topics Is Open
Feeling inspired by all the great sessions you’ve attended? Help shape the curriculum for CHEST 2027, October 24 to 27 in Vancouver, by submitting topic ideas from areas you’re passionate about, topics affecting your practice, or new technologies you’d like to learn more about. The submission deadline is Tuesday, December 1, at 2 pm CT.



